CDL200 Antibacterial Protein for Rapid C. Difficile Lysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing antibiotics are ineffective against antibiotic-resistant Clostridioides difficile bacteria, leading to increased infections and secondary problems like intestinal microbial community disruption, necessitating a new antibacterial substance with rapid therapeutic effects.

Innovation Solution

Development of an antibacterial protein CDL200 with a specific amino acid sequence (SEQ ID NO: 1) that can lyse Clostridioides difficile, produced using the Top10-CDL200 strain, and formulated into a pharmaceutical composition for treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to treat Clostridioides difficile infections, then therapeutic effects are achieved against sensitive strains, but antibiotic resistance develops leading to treatment failure

Engineering Contradiction:

Improvetherapeutic effectVSAvoidantibiotic resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts the essential antibacterial function from conventional antibiotics and implements it through a completely different mechanism - using bacteriolytic proteins that directly lyse bacterial cells through pore formation and membrane disruption, rather than relying on antibiotic targets that bacteria can mutate to resist

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the fundamental parameter of antibacterial action from inhibition of cellular processes (antibiotics) to direct physical lysis of the cell membrane (bacteriolytic proteins), thereby overcoming resistance mechanisms that evolved against traditional antibiotics

Inventive Principle:

Principle #35Parameter changes

2Reliability

If broad-spectrum antibiotics are used to treat infections, then pathogenic bacteria are eliminated, but normal intestinal microflora balance is disrupted

Engineering Contradiction:

Improveinfection treatmentVSAvoidmicrobial community disruption

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies the principle of local quality by designing bacteriolytic proteins with specific recognition capabilities for pathogenic bacteria only, allowing selective action against target pathogens while leaving beneficial microflora untouched, thus treating infections without disrupting the microbial ecosystem

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses specific molecular recognition mechanisms as intermediaries, where the bacteriolytic proteins recognize and bind to unique surface structures on pathogenic bacteria, enabling selective targeting without affecting other bacterial species in the intestinal microbiome

Inventive Principle:

Principle #24Intermediary (Mediator)

3Adaptability or versatility

If existing antibacterial substances are developed, then treatment options are expanded, but rapid therapeutic effect is not achieved against resistant strains

Engineering Contradiction:

Improvetreatment optionsVSAvoidtherapeutic effect speed

Core Design Contradiction:

Adaptability or versatilityVSSpeed

Solution Approach 1:

The patent employs bacteriolytic proteins that rapidly penetrate and disrupt bacterial cell membranes, achieving quick lysis and death of resistant bacteria, thereby providing fast therapeutic action that skips the slow process of inhibiting bacterial growth and waiting for cell death

Inventive Principle:

Principle #21Skipping (Rushing through)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

CDL200 effectively targets antibiotic-resistant Clostridioides difficile, minimizing side effects on normal flora and providing rapid therapeutic benefits against infections and diseases.

Implementation Method 1

The CDL200 protein specifically binds to Clostridioides difficile and forms pores in the bacterial cell membrane

Methodology Applied

Scientific EffectPore formation:

Implementation Method 2

CDL200 effectively targets antibiotic-resistant Clostridioides difficile, minimizing side effects on normal flora and providing rapid therapeutic benefits against infections and diseases

Methodology Applied

Scientific EffectBacteriolytic activity:

Data Source

PatentUS12503494B2Antibacterial protein CDL200 having lytic activity against <i>Clostridioides difficile</i>

Publication Date: 2025.12.23 INTRON BIOTECHNOLOGY INC

AI summary

The present invention relates to an antibacterial protein CDL200 with an antibacterial activity specific against Clostridioides difficile. More specifically, the present invention relates to an antibacterial protein CDL200 specific to Clostridioides difficile that may infect and cause disease in animals including humans, the antibacterial protein CDL200 being characterized by having the ability to specifically lyse the Clostridioides difficile and containing the amino acid sequence represented by SEQ ID NO: 1. In addition, the present invention relates to a pharmaceutical composition for treating an infection or disease caused by Clostridioides difficile, the composition containing the antibacterial protein CDL200 specific to Clostridioides difficile as an active ingredient.